Toward asleep DBS: cortico-basal ganglia spectral and coherence activity during interleaved propofol/ketamine sedation mimics NREM/REM sleep activity

Jing Guang1,2,✉, Halen Baker2,✉, Orilia Ben-Yishay Nizri2,8, Shimon Firman2,8, Uri Werner-Reiss2,6, Vadam Kapuller4,5,6, Zvi Israel7 and Hagai Bergman1,2,7

Deep brain stimulation (DBS) is currently a standard procedure for advanced Parkinson’s disease. Many centers employ awake physiological navigation and stimulation assessment to optimize DBS localization and outcome. To enable DBS under sedation, asleep DBS, we characterized the cortico-basal ganglia neuronal network of two nonhuman primates under propofol, ketamine, and interleaved propofol-ketamine (IPK) sedation. Further, we compared these sedation states in the healthy and Parkinsonian condition to those of healthy sleep. Ketamine increases high-frequency power and synchronization while propofol increases low-frequency power and synchronization in polysomnography and neuronal activity recordings. Thus, ketamine does not mask the low-frequency oscillations used for physiological navigation toward the basal ganglia DBS targets. The brain spectral state under ketamine and propofol mimicked rapid eye movement (REM) and Non-REM (NREM) sleep activity, respectively, and the IPK protocol resembles the NREM-REM sleep cycle. These promising results are a meaningful step toward asleep DBS with nondistorted physiological navigation.

INTRODUCTION

It is estimated that 10 million people worldwide suffer from Parkinson’s disease (PD). While dopamine replacement therapy offers a good short-term solution, after five to 10 years, severe side effects emerge. Currently, one of the most promising long-term treatments available is deep brain stimulation (DBS). The DBS procedure aims to surgically implant leads that enable high-frequency stimulation of specific nuclei in the basal ganglia. The most common targets are the subthalamic nucleus (STN) and the internal segment of the globus pallidus (Gpi). Behaviorally, this results in a vast improvement in PD symptoms1–4. DBS is not only used for PD patients but also additionally for patients with dystonia, essential tremor, and psychiatric disorders5–8, suggesting that enhancement of this technique would be quite far reaching. To accurately reach the target of the DBS lead, a neural navigation system that requires brain electrophysiological signals from the awake patient may be used9,10. Some patients avoid DBS therapy due to the fear of undergoing awake brain surgery11, leaving a wide gap for therapeutic improvement.

Propofol is currently the most commonly used sedative-hypnotic drug in clinical anesthesia. In Parkinsonian patients, propofol might cause dyskinesia (probably due to paradoxical excitation) or abolish tremor12. Nevertheless, many publications support the use of propofol in PD patients because of its fast onset and short duration of action. In fact, propofol is often used during the scalp incision and drilling of the burr-hole during DBS surgery. On the other hand, studies in human subjects undergoing DBS procedure demonstrated a significant modulation of the neuronal discharge of the basal ganglia DBS targets in response to propofol sedation13,14. Changes in thalamo-cortical activity have also been reported under propofol15,16. These changes in cortex and STN/Gpi discharge rate and pattern might interfere with the detection of the DBS targets. However, the short washout period of propofol may offer an ideal solution when used interleaved with a nondisruptive sedative.

Ketamine, a dissociative agent, is less commonly used in neuroanesthesia due to its reputation as causing increases in the cerebral blood flow and metabolism, increased cranial pressure (ICP), and frightening hallucinations. However, recent studies revealed that ketamine does not affect cerebral metabolism17–19 or ICP20, and that subanesthetic doses of ketamine are associated with good subjective experience21. Ketamine has analgesic effects and has in fact shown promise as a treatment for depression22. Ketamine also has the added advantage over other sedatives in that it is possible to check the therapeutic and adverse stimulation effects, including internal capsule recruitment, paresthesia, speech, and eye-movement deficits, as in the awake patient23. In animal models, ketamine increases the spontaneous gamma and ultra-slow oscillations in the cortical and basal ganglia nuclei24–29. Akinesia of Parkinson’s patients and animal models is associated with beta oscillations30, while Parkinson’s therapies (L-DOPA and DBS) are associated with gamma oscillations31,32. This leads us to believe that ketamine sedation may be less disruptive to the navigation system that uses beta oscillations for detection of DBS targets and subdomains33,34 and potentially a good choice for use in DBS surgeries.

The relationship between sleep and sedation is multifaceted and is still not completely understood. Due to the variations in the

1Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel. 2Department of Medical Neurobiology, The Hebrew University of Jerusalem, Jerusalem, Israel. 3Department of Anesthesiology, Critical Care Medicine, and Pain Management, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. 4Department of Pediatric Surgery, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. 5Asuta-Ashdod University Medical Center, Ashdod, Israel. 6Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. 7Department of Neurosurgery, Hadassah Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. 8These authors contributed equally: Jing Guang, Halen Baker, Orilia Ben-Yishay Nizri, Shimon Firman. ✉email: Jing.Guang@mail.huji.ac.il

Published in partnership with the Parkinson’s Foundation
mechanisms of action of sedative agents, there is a wide range of reported similarities and differences between natural sleep and any given sedative medication\textsuperscript{35,36}. For patients already ill, good quality sedation is essential to their well-being. Thus, mimicking natural sleep with sedation could greatly benefit them both during and following surgeries. To this end, we aimed to test the effects of propofol and ketamine sedation and an interleaved propofol-ketamine (IPK) sedation protocol on the neural activity in the cortex-basal ganglia circuit. We hypothesize that propofol would enable the more invasive stages of DBS procedures (like drilling of the burr-hole) and due to its fast action its effects on the basal ganglia would not be persistent. In a complementary way, ketamine may be undistruptive to the neural navigation system while still providing the necessary dissociative and analgesic effects needed during this less invasive stage of the surgery. If correct, this will allow sedation to be safely given during navigation and lead implantation in DBS surgery and greatly improve the experience of these patients.

RESULTS
The experiments were performed on two female African green monkeys (\textit{Chlorocebus aethiops sabaeus} (vervet), weight: \textasciitilde4 kg). All experimental protocols were conducted in accordance with the National Institutes of Health \textit{Guide for the Care and Use of Laboratory Animals} and The Hebrew University of Jerusalem guidelines for the use and care of laboratory animals in research. Before the surgery, the nonhuman primates (NHPs) were introduced to the recording room and trained to sit and sleep in a specially made primate chair. The first surgery consisted of a craniotomy and implantation of a recording chamber, head holder, and EEG electrodes. The second surgery involved the implantation of a subcortaneous porcetentral venous catheter. The experiments included neural recording (Fig. 1a), while the animal was under sedative medications and naturally sleeping. The recordings were carried out before and after systemic treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) neurotoxin and induction of Parkinson’s symptoms (Fig. 1b and Supplementary Table 1) and with careful monitoring of the vital signs (Fig. 1c). After the end of the recording, the NHP’s were rehabilitated and moved to the Israel Primate Sanctuary (www.ipsf.org.il).

First, titration sessions were performed for each sedative drug and each NHP to establish a moderate sedation dose (Fig. 1d). The sedation sessions consisted of 1 h of saline baseline followed by 1 h of sedation (propofol/ketamine) and finally 1 h of saline washout. Eye open/close state and blinking response to air-puff stimulation to the eye (Fig. 1e, Supplementary Table 2), polysomnography, including electroencephalogram, electrooculo-gram, and electromyogram (EEG, EOG, EMG, Fig. 1f) and local field potential and spiking activity (LFP and SPK, Fig. 1g) from the frontal cortex and globus pallidus external segment (GPe) were recorded during all three phases of each session.

Currently, DBS physiological navigation systems use the independent parameters of discharge rate (or total power of spiking activity) and discharge pattern (e.g., power spectrum densities normalized to the total power). The total power of the spiking activity is often used for the detection of the borders of the structures, while the spectral signature enables the discrimination of the target subdomains (STN and GPI motor domains are characterized by theta and beta oscillations\textsuperscript{35,34}). Both parameters can be affected by sedation agents. The firing rate and total power of spiking activity were modulated during propofol and ketamine sedation (Supplementary Fig. 1). Here, we will mainly discuss the effect of these sedation agents on the discharge pattern. The power spectrum densities and pairwise coherence were calculated as a function of time (spectrograms and coherograms) for all EEG, LFP, and SPK recordings and normalized by frequency (i.e., by their total power/coherence) and then by the saline baseline period (by time, Fig. 1h).

Propofol and ketamine differentially modulate power and synchronization

To establish the individual characteristics of propofol and ketamine in the healthy and parkinsonian conditions, we investigated power spectrum changes during the sedation period for each recording target and modality (Fig. 2, Supplementary Fig. 2). This revealed that in comparison to the saline baseline in all recording modalities (EEG, EOG, EEG, LFP, and SPK) and targets (cortex and basal ganglia) propofol sedation increased low-frequency power. Particularly, propofol sedation boosted delta frequency power, in EEG and LFP of both the frontal cortex and GPe (Fig. 2a, b). On the other hand, ketamine sedation decreased low-frequency power and increased high-frequency power, particularly gamma frequency power, in all modalities (Fig. 2c, d). MPTP treatment and the emergence of Parkinson’s symptoms resulted in changes in neural activity (Supplementary Fig. 3). Nevertheless, there were no significant differences between the sedation effects in the parkinsonian condition and the healthy condition (Fig. 2a–d, left and right subplots).

Similarly, we performed an exploration of the pair-wise synchronization (coherence) of EEG, cortex, and basal ganglia LFP and spiking activity. We found propofol sedation increased low-frequency synchronization while ketamine increased high-frequency synchronization in, and between the frontal cortex and basal ganglia in both the healthy and parkinsonian conditions (Fig. 3, Supplementary Fig. 4).

Propofol and ketamine mimic the spectral signature of neural activity during NREM and REM, respectively

In order to examine the common properties of sleep stages and the two sedative agents, we calculated the spectrograms and coherograms of different sleep stages (Supplementary Fig. 5) for each modality. This revealed that in EEG, LFP, and SPK cortical and basal ganglia recordings NREM sleep increased low-frequency power, while REM sleep increased high-frequency power (Fig. 4a, b, Supplementary Fig. 6a). Not only were the power analyses of sedation and sleep effects similar but also the synchronization analyses (Fig. 4c, d, Supplementary Fig. 6b) also showed common characteristics. NREM showed an increase in low-frequency synchronization of the neural activity, while REM showed a decrease in low-frequency synchronization and an increase in high-frequency synchronization. However, one way in which propofol and ketamine do not mimic the NREM/REM cycle is in the EMG and EOG recordings (Supplementary Fig. 7). Ketamine does not seem to induce atonia (full muscle relaxation) as seen in REM sleep nor does it cause the namesake rapid eye movements of REM sleep (Fig. 1f vs. Supplementary Fig. 5c).

Interleaved propofol-ketamine can imitate the dynamics of the sleep cycle

Finally, to test if the effects of propofol and ketamine remain when simulating a natural sleep cycle we created an interleaved propofol and ketamine sedation session in which propofol and ketamine were administered such that a propofol–ketamine–propofol–ketamine–propofol cycle was established. In this regimen, propofol was administered for 40 min, directly followed by ketamine sedation for 20 min.

Similar to the changes observed in natural sleep from NREM to REM, the interleaved propofol-ketamine (IPK) sedation protocol followed the changes in spectrum and synchronization shown in the neural activity during propofol and ketamine sedations alone. Low-frequency power and synchronization increase during propofol followed by high-frequency power
and synchronization increases during ketamine (mimicking NREM and REM respectively, Fig. 5, Supplementary Fig. 8).

DISCUSSION
This study aimed to characterize the electrophysiological changes during moderate ketamine sedation, propofol sedation, interleaved propofol-ketamine (IPK) sedation protocol, and natural sleep using polysomnography and neuronal activity of the cortico-basal ganglia neuronal network. In EEG and LFP recordings from the frontal cortex and the basal ganglia, ketamine was found to increase high-frequency power and synchronization, while propofol was found to increase low-frequency power and synchronization. These results were corroborated in the IPK protocol. The
dynamic between propofol and ketamine was found to be a fast one and to mimic the spectrum and synchronization changes of NREM and REM natural sleep.

Classically, the target for DBS for PD is the STN, while for dystonia it is the GPi. Here, due to the recording and time constraints, imposed by the need for 2–3 days’ interval between the sedation sessions and for minimization of whole duration of NHP experiments, we felt it was most appropriate to record and characterize the GPi. The three layer model of the basal ganglia positions the GPi in the middle layer, receiving from the SNr, but projecting to the thalamus and the cortex. The GPi layer contains the Nigrostriatal and Thalamostriatal projections. It shows the frequency range for the high/low power and synchronization differences. Ctx, cortex. ECG, electrocardiogram, EEG, electroencephalogram, EMG, electromyography, EOG, electrooculography, EtCO2, end-tidal CO2, Frt, frontal, GPe, globus pallidus, external segment, Ktm, ketamine, LFP, local field potential, MSC, magnitude-squared coherence, NHPs, nonhuman primates, Ocp, occipital, Ppf, propofol, Prt, parietal, Sal, saline, SPK, spiking.

In general, sedatives are kept consistent across a procedure (barring unexpected events) keeping the brain state consistent as well, unlike the cyclical, staged, sleep rhythm, and sedation interval routines used in intensive care units. Consequently, it is unsurprising that up to 80% of patients report waking up from the sedation with a feeling of drowsiness signifying that sedation does not equate to natural sleep. Moreover, the natural nocturnal sleep has been found to be markedly disturbed following surgical procedures. Disturbances of sleep are highly prevalent in basal ganglia-related neurodegenerative disorders, particularly PD. Enabling more restful sedation could greatly benefit these patients who already suffer from sleep difficulties.

Both sedation and the sleep cycle reversibly alter consciousness. The type of sedative or sleep stage can determine what type and level of consciousness one experiences. Contrary to previous theories that anesthesia and sleep are states in which the brain is switched off, newer studies suggest that the brain's electrophysiology is modified in accordance with consciousness level. Further, recent research reports similar electrophysiological changes, namely modification of evoked alpha and gamma power, during ketamine sedation and REM sleep compared to propofol anesthesia and NREM sleep. The authors argue that ketamine sedation and REM sleep are both states of disconnected consciousness while propofol anesthesia and NREM sleep are states of unconsciousness. These results are very much in line with our findings of high and low-frequency power alterations group-ketamine with REM sleep and propofol with NREM sleep. Further, though both the propofol and ketamine sedation recording sessions were performed at what is considered moderate sedation by the American Society of Anesthesiologists (ASA), this and other reports suggest we should be considering the above definitions of dissociated and reduced consciousness instead when discussing the electrophysiology of the brain.

Though ketamine was highly touted for its cardiorespiratory preservation properties after its invention in the 1960s, over the years it has become less commonly used due to the view that it increased salivation and upper airway secretions, its rise in popularity as a drug of abuse, and the fear of instigating frightening hallucinations. Hallucinations do seem to occur in up to 50% of adult sedations under ketamine, suggesting that limited use is warranted. However, the content of the hallucinations might be context dependent. Further, the power of suggestion could potentially affect the content of the hallucination and its connotations. The IPK protocol may help in reducing ketamine's adverse effects since ketamine hallucinations have been reportedly blocked by prior or co-administration of GABA agonists, like propofol, in humans undergoing surgical procedures.
Propofol is the most commonly used sedative in the OR today and for good reason, it is fast acting and effective. These properties make it an excellent choice for surgeries with aspects that might be anxiety-provoking. Additionally, procedure-related pain control may be accomplished by systemic analgesic medication administration, and performance of local anesthesia infiltration and/or supplemented nerve blocks as done routinely nowadays. Our IPK protocol harnesses the positive properties and concerns of both propofol and ketamine to deliver the best experience for the DBS patient and surgeon/electrophysiologist. We propose propofol be used during the scalp incision and burr-hole creation due to the frightening nature of this stage of surgery. Then, the lights in the OR should turn down and the staff should make an effort to create a calm environment while ketamine is administered (mimicking the conditions in our dark and noise attenuated recording room). Ketamine sedation should continue for the short period of neural navigation, limiting the time in which hallucinations can occur. Once navigation has been completed, the patient should be switched back to propofol for the incision and burr-hole creation in the second hemisphere or for the closure of the wounds and the surgical fields. We believe this addresses both main concerns by minimizing hallucination possibility through limited-time exposure and creating a relatively relaxed context while still enabling the use of neural navigation.

Today, there is a significant diversity of DBS techniques and paradigms. Many centers perform microelectrode physiological recording and assessment of the therapeutic window of high-frequency stimulation before lead implantation. In these centers, interleaved propofol-ketamine asleep DBS may be the preferred method. While our study gives a solid starting point toward asleep DBS, it does have some limitations. First, African green monkeys share a similar dopaminergic system to that of humans and therefore it is reasonable to use them as a model for Parkinsonism and to record from the basal ganglia. However, they are still models so no absolutely conclusive answer can be given regarding humans. Second, as commonly done and recommended in NHP studies our study had a small sample size of two female NHPs. Ketamine’s antidepressant effects may be sex dependent, where females appear to be more responsive to lower dose ketamine, probably due to ketamine interactions with brain estrogen receptors. Future studies should explore sex difference in the short- and long-term responses to ketamine sedation. Third, the parkinsonian NHPs in this study were only treated with dopamine.
replacement therapy for a short time before recording while in human DBS patients they are usually treated with dopamine replacement therapy for many years before surgery. We cannot discount the effects of chronic dopamine therapy on electrophysiological properties and recordings. Additionally, though the amount of time proposed to use ketamine is limited through the amount of time proposed to use ketamine is limited though the amount of time proposed to use ketamine is limited though the amount of time proposed to use ketamine is limited though the amount of time proposed to use ketamine is limited.

Fig. 3 Propofol and ketamine increase and decrease low-frequency synchronization, respectively, in cortico-basal ganglia neuronal activity. a The normalized magnitude-squared coherograms of all pairs of EEG, Ctx LFP/SPK, and GPe LFP/SPK during saline baseline, propofol sedation, saline washout before (lower left) and after MPTP-treatment (upper right). The 1st row/column shows coherograms within the same signal type (e.g., EEG to EEG), other subplots show coherograms between different signal types. The lower bar represents 1-hour time periods (averaged through all coherograms within one session) between high-frequency (12–40 Hz) and low-frequency (0.5–4 Hz) coherence domains before (left) and after (right) MPTP-treatment. Top black horizontal bar represents a significant difference compared to saline (p < 0.05, Kruskal–Wallis test). Lower. The change from saline baseline of the normalized high/low synchronization difference during saline (upper, green minus empty green), propofol sedation (upper, blue minus empty blue), saline washout (upper, cyan minus empty cyan) before (left), and after MPTP-treatment (right). P-value is given, Kruskal–Wallis test. c, d Same conventions as a, b. during ketamine. Color represents saline baseline (green), ketamine sedation (red), and saline washout (orange). The number of pairs (a, c) and sessions (b, d) is given for both monkeys for each subplot. Abbreviations as in Fig. 1.
methods}

The study's ethical permission number is MD-18-15449-5. The Hebrew University of Jerusalem is an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) internationally accredited institute.

Surgery

Surgical preparation of the NHP included two procedures carried out under general and deep anesthesia (Isoflurane and N₂O inhalation anesthesia, induction by IM 0.1 mg/kg Domitor and 10 mg/kg Ketamine) and in aseptic conditions. The first surgery consisted of a craniotomy and implantation of the STN, GPi, and SNr to direct recording of neural activity during DBS, the SNr was left intact in the second surgery. The second surgery was performed 14 days after the first surgery, when the first surgery wounds were fully healed. The second surgery included the implantation of a DBS lead into the STN, GPi, and SNr. The high voltage of the DBS was turned on 3 days after the second surgery, and the animals were monitored daily during the following weeks for signs of neurological deficit. If no signs of neurological deficit were observed, the animals were transferred to the sleep laboratory for polysomnography and neural activity recordings during natural sleep.

The current study should be carefully followed by a prospective human study that hopefully would lead to a paradigm change in DBS practice enabling high-quality physiological navigation during asleep DBS.
Interleaved Propofol-Ketamine (IPK) sedation protocol shows a similar trend of power/synchronization changes as sedation induced by propofol and ketamine alone. a The normalized power spectrograms of EEG/EMG/EOG (1st row), Ctx LFP/SPK (2nd row) and GPe LFP/SPK during IPK before (left) and after (right) MPTP-treatment. Lower bar represents time periods of saline baseline (green), propofol sedation (blue), ketamine sedation (red) and saline washout (cyan). b. Upper. The normalized high/low power difference (averaged through all spectrograms within one session) between high frequency (12–40 Hz) and low frequency (0.5–4 Hz) mean power before (left) and after (right) MPTP-treatment. Top black horizontal bar represents significant difference compared to saline (p < 0.05, Kruskal–Wallis test). Lower. The change from baseline of the normalized high/low power difference during saline (upper, green minus empty green), propofol sedation (upper, blue minus empty blue), ketamine sedation (upper, red minus empty red), saline washout (upper, cyan minus empty cyan) before (left) and after (right) MPTP-treatment. P-value is given, Kruskal–Wallis test. Statistics applied to adjacent sedation stages. c. The normalized coherograms of all pairs of EEG, Ctx LFP/SPK and GPe LFP/SPK during IPK before (lower left) and after (upper right) MPTP-treatment. The 1st row/column shows coherograms within same signal type (e.g., EEG to EEG), other subplots show coherograms between different signal types. d. Same conventions as b for synchronization difference. Number of sites (a), pairs (c) and sessions (b, d) is given for both monkeys for each subplot. Abbreviations as in Fig. 1.

During the first surgery, a 27×27 mm polyetherimide (PEI, MRI compatible, Alpha-Omega, Nof HaGalil, Israel) recording chamber and a head holder were surgically implanted in the animal’s skull (see details in previous publications of the lab39–41). The chamber was positioned in a suitable location that allowed electrophysiological recordings from the frontal cortex and external segment of the globus pallidus (GPe). The location of the chamber was determined according to a primate stereotaxic atlas42. During the surgery, six EEG screw electrodes were positioned bilaterally, in the frontal, parietal and occipital positions of each hemisphere in the NHP’s skull.

In the second surgery, a subcutaneous ported vascular catheter (port-a-cath, Medcomp, PA, USA) was placed. The procedure for insertion of a port includes the formation of a subcutaneous pocket for the port, fixation of the port to the fascia by sutures, tunneling of the vascular catheter, and cannulation of the superior vena-cava using Seldinger’s Technique. The procedure was carried out under ultra-sound imaging, and the final location of the catheter was verified by X-ray.

In addition to general anesthesia, the area of the surgical incisions was infiltrated with local anesthetic (2 ml of Bupivacaine 0.25%). Perioperatively, the animal was treated with antibiotics (Ceftriaxone 35 mg/
kg, PanPharma, Luitré-Dompierre, France), steroids (Dexamethasone 0.5 mg/kg, Kern Pharma, Barcelona, Spain), and analgesic (Diprynone 20 mg/kg, Teva, Petach-Tikva, Israel) medicine. It was allowed at least 4–5 days of recuperation after surgery before resuming training and experimental work.

To maintain patency of the port and intravascular tubing heparin (2.5–3 ml/100 ml, Heparin Bond, Interfarma, Switzerland) was used to flush the port after the recording session and at least once weekly when no recordings took place. The cranial chamber was flushed every other day (including before and after recording) with a saline-neomycin solution, and dura scrapping was done several times (every 4–6 weeks) under IM domitor (0.1 mg/kg) and ketamine (10 mg/kg) sedation to enable penetration of the dura by microelectrodes.

**MRI imaging**

Following recovery from surgery, the NHPs underwent a 3 T MRI examination (Fig. 1a) to verify the correct placement of the chamber and to determine its precise stereotaxic location (see details in previous publications of the lab[2]). The imaging procedure was carried out, while the NHP was sedated with IM domitor (0.1 mg/kg) and ketamine (10 mg/kg).

**Sedation procedure**

**Recording session protocol.** The NHPs were living in an open yard with companions when there are no sedation requirements. Recording sessions were performed approximately once every 2–3 days in a pseudo-randomized order. Each session consisted of a saline baseline, sedation, and saline washout period, each lasting 1 h. The sedation agents used were propofol (Raz Pharmaceuticals, Kadima Zoran, Israel or B Braun, Melsungen, Germany), ketamine (Vetoquinol, Lure Cedex, France), dexmedetomidine (Kalceks, Riga, Latvia), remifentanil (Mylan, Canonsburg, PA), and scopolamine (Sterop, Brussels, Belgium). For IPK session, 20 min–20 min–40 min–20 min–20 min of propofol–ketamine–propofol–ketamine–propofol (without last propofol for IPK sessions of monkey Ch before MPTP-treatment) were administered between 1-h saline and 1-h saline washout. Here, we report only on ketamine, propofol, and IPK effects.

**Fasting.** The evening before sedation the NHP was taken from the open yard where she is normally group housed and placed, usually with one of her peers, into a clean cage with no food and ad-libitum water. The sedation sessions were carried in the day after. Two to three hours before sedation administration the water access was closed. During the sedation session, vital signs (heart and respiration rate, end-tidal CO2) were monitored (Fig. 1c). Pulse oximetry and noninvasive blood pressure measurements were found to be less reliable in our setup and were not used in this study. Fasting reset limits for ending sedation (e.g., end-tidal CO2 > 60 mmHg) were never reached in this study. Following the conclusion of the experimental session, the monkey was again placed in a clean cage. Then, at ~45 min intervals, and depending on their clinical status, the water access was opened followed by a bell pepper and finally their normal pellet food. The NHP’s were given at least 2–3 days to rest and recover between sedation sessions.

**Titration procedure.** In order to ensure that the monkey was at a consistent moderate level of sedation, titration sessions were performed for each drug. In these sessions, a low infusion rate was first employed, slowly raising the rate in 15–20 min steps until the desired level of sedation was achieved. No more than 1 h of sedation was given per day. The level of sedation was based on the amount of time the monkey’s eyes were closed and blink in response to air-puff stimulation, which was directed to the eye. The air-puff was given once between 30 and 120 sec (monkey Ch) or twice with a minimal 30 sec interval between 20 and 280 sec (monkey Cs) into each 6-minutes’ time block randomly. Fig. 1d shows the details of the titration process for each drug.

**Drug preparation.** For every sedation session, sterile normal saline (NaCl 0.9%) was drawn into a 60 ml syringe and placed in the infusion pump (Injektomat Agilia, Fresenius Kabi). During the baseline period, the rate of infusion was set to 3 or 15 ml/h (monkey Ch and Cs, respectively), during sedation, the total rate of the infusion (drug + saline) was 15 or 20 ml/h (monkey Cs and Ch, respectively) and during the washout, the rate of saline infusion was kept at the same level as during sedation. The rate of the infusion was constant over the 1-h period, i.e., no target-control infusion (TCI) techniques were used.

**Propofol.** 20 ml vials of 10 mg/ml (1%) propofol were drawn into a 60 ml syringe. Infusion rate during sedation sessions was set according to the NHP’s weight, i.e., ~3 or 4.8 ml/h, approximately 120 or 190 mcg/min/kg for 4.2 kg NHP.

**Ketamine.** 0.5 ml of 100 mg/ml ketamine was mixed with 49.5 ml normal saline in a 60 ml syringe. Infusion rate during sedation sessions was set according to the NHP’s weight, i.e., 10.1 ml/h, ~40 mcg/min/kg for 4.2 kg NHP.

**Port-a-cath protocol.** Before every recording, the skin around the port was cleaned several times with chlorhexidine 2% in ethanol 70% solution. A sterile field was prepared. A noncorning needle (MiniLoc, Bard, Salt Lake, USA) was inserted into the proper puncture site. The dead space of the port and vascular catheter (previously locked with heparin) was drawn and the port’s patency was checked by flushing it with 5 ml of normal saline. At the end of each of the recording sessions, the port was locked with 3 ml of heparin (100 IU/ml). The noncorning needle was removed and the skin covering the port was sterilized with chlorhexidine 2% in ethanol 70% solution. The hair around the port area was clipped roughly every week.

**Induction of Parkinsonian symptoms**

The NHPs were treated with MPTP-hydrochloride (Sigma, Israel) in a negative pressure isolated room to induce parkinsonism. Five IM injections of 0.35 mg/kg/injection were made over the course of four days (two injections on the first day) under ketamine (10 mg/kg IM) sedation. The NHP was moved back to their previous room 72 h after the last MPTP injection. Before, during and following induction of parkinsonism a modified Benazzouz primate parkinsonism scale[3] was used to assess symptoms severity level (Fig. 1b).

One week following the first MPTP injection, the NHPs were severely akinetic and unable to feed themselves. The experimenters fed the NHPs twice a day, seven days a week with a pediatric nasogastric tube. A single feeding dose equals ~30 cc water and 50–70 cc of Ensure Plus (Abbott Laboratories, Abbott Park, Illinois), a high calorie (1.5 Kcal/cc) nutritional shake. The dopamine replacement therapy 1/8–1/2 tablet, 250 mg L-DOPA and 25 mg carbidopa per tablet (Dopicap, Teva Pharmaceutical Industries, Israel) was administered with every nasogastric feeding. Neuronal recordings during the parkinsonian condition began when the animal exhibited severe parkinsonian symptoms approximately 7 days after the first injection. Twelve hours before recording sessions, dopamine replacement therapy was stopped to allow for washout. The Parkinsonian symptoms were stable all over the recording period (Fig. 1b, top subplot).

**Experimental set-up**

The experiments were performed using two separate rooms. 1. An experimental room, where vital signs (Nasal End-tidal CO2, respiratory rate, ECG, and heart rate) were monitored (Mindray, BeneVision N12, Shenzhen, China) and the experimenters manipulated the infusion pumps, the electrode vertical positions, operated the data acquisition tools, and performed on-line analysis (e.g., spike sorting). 2. A noise attenuated (Industrial Acoustics Company, Controlled Acoustic Environment, IL, USA) recording room, in which the NHP was located. The recording room was dark during the recording and infrared cameras (Metaphase Technologies, Inc., PA, US) were used to monitor the NHP. The live video (Fig. 1a, d–g, ImagingSource, NC, USA) recording was collected at 50 Hz during all sessions allowing the researchers to monitor the animal and determine whether the NHP’s eyes were open or closed. This was then synchronized with the neural data collected using Alphalab SmR (Alpha-Omega Engineering, Nof Hagalil, Israel). Fig. 1a depicts a schematic diagram of the experimental set-up.

**Polysomnography**

We recorded the electrocorticography (EOG) signal bilaterally using disposable subdural needle electrodes (Rhythmlink, Columbia, US). We placed one electrode 1 cm below the left outer canthus, and another electrode 1 cm above the right outer canthus. We recorded the electromyography (EMG) signal from the NHP’s trapezius muscle contralateral to the port by two disposable subdural needles placed ~1 cm
apart. We continuously recorded the surface electroencephalogram (EEG) signal, using the chronic EEG electrodes that were implanted during the surgery. Six electrodes were used—two frontal, two parietal, and two occipital. A cranial implant fastener (slip under the skull and held in place with a double nuts, 6-YCI-06L, Crist Instruments, Maryland, USA) was used as a ground and a reference. The EEG, EMG, and EEG were sampled at 2750 Hz. Detailed polysomnography methods can be found here66.

**Behavioral Measures**

To model the physical touch that is often used to assess a patient's sedation level (eyelash reflex), we measured the blink evoked by a short duration air-puff directed at the eyes of the NHP using a computer-controlled solenoid valve (SD Instruments, CA, USA) connected to a pressurized gas tank. The air-puff was administered randomly in time with a pressure of 8 bars and a duration of 0.2 sec.

**Electrophysiological recording procedures**

During recording sessions, the NHP's head was immobilized by a head holder. Then, eight independently controlled glass-coated tungsten microelectrodes (impedance 0.3–1.2 MΩ at 1000 Hz) were advanced into the brain (EPS; Alpha-Omega Engineering, Nof Hagalil, Israel. Smallest step, 1 μm) towards the target regions67. The difference signal (0.1–0000 Hz), spiking activity (SPK, 300–9000 Hz) and local field potential (LFP, 0.1–300 Hz) were recorded. Cells were selected for recording as a function of their isolation quality and optimal signal-to-noise ratio. Online, the researchers monitored the quality of the cells and noted defining characteristics, discharge rate and a letter-grade rating of the overall quality of the recorded spikes. The data were continuously sampled at a frequency of 44 KHz (raw and SPK data) and 1375 Hz (LFP data) by 16 bits analog to a digital converter (SnR, Alpha-Omega). Offline, we used the isolation score as a criterion to define an appropriate unit database for subsequent analyses68.

**Data analysis methods**

All data analysis was conducted using in-house Matlab (MathWorks, Natick, MA; version R2018b) scripts.

Eye closure analysis: for each sedation session and sleep night session, a modified version of eye open/closed detection tool69 was used. An area of interested (AOI) was selected to cover the pixels of two eyes and applied to frames of the whole session (nights). The averaged grayscale and 1st principal component of AOIs were used to form a 2-D space, and 2-D threshold were manually selected to define eye open/close of frames.

Air-puff stimulation analysis: for each sedation session, the video frames of saline (all frames), sedation (5 min after sedation initiation to washout), and washout (5 min after washout initiation) were used to calculate eye closure proportion for each stage. Frames were aligned to the end of air-puff to show eye closure rate around air-puff for each stage. Sequential eye-closed frames, which were longer than 1 sec were marked as long duration closure frames, otherwise, they were marked as short duration closure (blink) frames. The same eye closure proportion analysis was applied to all, short and long-duration eye closures.

Sleep staging: to determine the sleep stages, the polysomnography measurements of EEG (filtered 0.1–35 Hz), EOG (filtered 0.1–35 Hz), EMG (filtered 10–100 Hz), and eye state (open/closed) were used. Sleep staging was done using a semiautomatic staging algorithm (custom software) which took 10 sec nonoverlap epochs and clustered them based on three features: (i) the average ratio of high/low EEG power across all contacts. The average power at 15–25 Hz (related to waking) was divided by the average power at 0.1–7 Hz (related to sleep); (ii) root mean square (RMS) of the EMG signal; and (iii) eye-open fraction (open/all). Every 10 sec epoch was represented as a point in three-dimensional feature space, usually forming three clusters: for wakefulness (high EMG RMS, increased EEG high/low ratio, eye-open fraction close to 1), NREM (low EMG RMS, decreased EEG high/low ratio, eye-open fraction close to 0), and REM (very low EMG RMS, increased EEG high/low ratio, eye-open fraction close to 0). Before semiautomatic clustering, a trained expert manually clustered 10–30% of the night epochs based on EEG, EMG, EOG, and eye open/close. The staging results provided by the semiautomatic algorithm were accepted for further analysis only if they matched the expert staging in more than 85% of the tested epochs. Two nights (monkey Ch) in which EMG RMS has no clear separation between REM and NREM were removed from the database. For further elaboration on sleep staging analysis see here67.

Spectrogram analysis: for each signal type (e.g., EEG, local field potential (LFP), spiking activity (SPK), etc.), Welch’s power spectral densities as a function of time (spectrogram) with 12 sec window, 6 sec overlap, frequency range 0.5 Hz to 100 Hz with 0.5 Hz resolution was calculated by 60 sec moving window with 30 sec step. DC (direct current, 0 Hz) was removed for each 60 sec window by subtraction of the window mean. The SPKs were rectified (by the absolute value function) to capture the low-frequency oscillations of the discharge rate68. To reduce the noise at specific frequencies, power densities of 40–52 Hz (for LFP/SPK related MSC) or total power densities were used to represent high/low difference of the spectrogram. For each sedation session (nights), all normalized high/low-power difference were normalized to capture the low-frequency oscillation of discharge rate, and sampling rate of pairs of signals was downsampled to the sampling rate of the signal with a lower sampling rate. To reduce the noise at specific frequencies, LFP-related MSC of 16.5–18 Hz, 48–52 Hz, 60 Hz, 99–100 Hz were linearly filled with MSC of the flanking frequencies. EEG-related MSC of 48–52 Hz, 60 Hz, 99–100 Hz was similarly linearly filled. The MSC for certain time bins were set to NaN, if the electrode position was not stable (for LFP/SPK related MSC) or total MSC was defined as an outlier by more than 1.5 interquartile ranges above the upper quartile or below the lower quartile for consequential 15 bins (8 min). The power densities of each time bin were normalized to one. Then the proportion of power density for each frequency was normalized to z-score of saline periods (Fig. 1h, top subplot). The normalized spectrograms were averaged within the same signal types.

Similar analysis was applied for nonoverlap epochs with 60 sec. The power densities were set to NaN, if the electrode position was not stable (for LFP/SPK) or total power densities were defined as outliers of segments of the same sleep stages. After normalization of total power in each time bin to one, the proportion of power density for each frequency was normalized to z-score of wake periods. The normalized spectrograms of wake, NREM and REM were aligned to its own initiation and averaged within the same signal types.

**Coherogram analysis:** for each pair of signal types (e.g., EEG-EEG, Ctx LFP-EEG, etc.), magnitude-squared coherence (MSC) as a function of time (coherogram) with 12 sec window, 6 sec overlap, frequency range 0.5–100 Hz with 0.5 Hz resolution were calculated by 60 sec moving window with 30 sec moving step. DC (direct current, 0 Hz) was removed for each pair for each 60 sec window by subtraction of the window mean of each signal. The SPK signal was rectified to capture the low-frequency oscillation of discharge rate, and sampling rate of pairs of signals was downsampled to the sampling rate of the signal with a lower sampling rate. To reduce the noise at specific frequencies, LFP-related MSC of 16.5–18 Hz, 48–52 Hz, 60 Hz, 99–100 Hz was linearly filled with MSC of the flanking frequencies. EEG-related MSC of 48–52 Hz, 60 Hz, 99–100 Hz was similarly linearly filled. The MSC for certain time bins were set to NaN, if the electrode position was not stable (for LFP/SPK related MSC) or total MSC was defined as an outlier by more than 1.5 interquartile ranges above the upper quartile or below the lower quartile for more than 15 bins (8 min). MSC values were bounded between zero and one and therefore are not linearly distributed. We used the Fisher z-transform to normalize the MSC distribution. The Fisher z-transformed squared root of MSC of each time bin in coherogram were normalized to one. Then the proportion for each frequency was normalized to z-score of saline periods (Fig. 1h, lower subplot). The normalized coherograms were averaged within the same pairs of signal types.

**Sleep staging: to determine the sleep stages, the polysomnography measurements of EEG (filtered 0.1–35 Hz), EOG (filtered 0.1–35 Hz), EMG (filtered 10–100 Hz), and eye state (open/closed) were used. Sleep staging was done using a semiautomatic staging algorithm (custom software) which took 10 sec nonoverlap epochs and clustered them based on three features: (i) the average ratio of high/low EEG power across all contacts. The average power at 15–25 Hz (related to waking) was divided by the average power at 0.1–7 Hz (related to sleep); (ii) root mean square (RMS) of the EMG signal; and (iii) eye-open fraction (open/all). Every 10 sec epoch was represented as a point in three-dimensional feature space, usually forming three clusters: for wakefulness (high EMG RMS, increased EEG high/low ratio, eye-open fraction close to 1), NREM (low EMG RMS, decreased EEG high/low ratio, eye-open fraction close to 0), and REM (very low EMG RMS, increased EEG high/low ratio, eye-open fraction close to 0). Before semiautomatic clustering, a trained expert manually clustered 10–30% of the night epochs based on EEG, EMG, EOG, and eye open/close. The staging results provided by the semiautomatic algorithm were accepted for further analysis only if they matched the expert staging in more than 85% of the tested epochs. Two nights (monkey Ch) in which EMG RMS has no clear separation between REM and NREM were removed from the database. For further elaboration on sleep staging analysis see here67.

Spectrogram analysis: for each signal type (e.g., EEG, local field potential (LFP), spiking activity (SPK), etc.), Welch’s power spectral densities as a function of time (spectrogram) with 12 sec window, 6 sec overlap, frequency range 0.5 Hz to 100 Hz with 0.5 Hz resolution was calculated by 60 sec moving window with 30 sec step. DC (direct current, 0 Hz) was removed for each 60 sec window by subtraction of the window mean. The SPKs were rectified (by the absolute value function) to capture the low-frequency oscillations of the discharge rate68. To reduce the noise at specific frequencies, power densities of 40–52 Hz (for LFP/SPK related MSC) or total power densities were used to represent high/low difference of the spectrogram. For each sedation session (nights), all normalized high/low-power difference were averaged within different signal types, then averaged through different sign types to represent the high/low-power difference of this sedation session (nights). The same frequency ranges were used for the coherogram to calculate the high/low synchronization difference.

**Rehabilation**

Following completion of the study, the NHP’s continued to be fed through nasogastric tube and were treated one to three times daily with dopamine replacement therapy. After partial recovery of the Parkinsonian symptoms (2–3 months after the MPTP injections), the head apparatus and the port-a-cath were removed under general anesthesia, perioperative antibiotics,
and analgesic treatment. As they improved, the NHPs were gradually reintroduced to their group starting with 10 min one-on-one time with another NHP, then one on one overnight and during feeding times, and finally full reintroduction. After parkinsonian symptoms were deemed minor (Fig. 1b, lower subplot) and the NHP showed the ability to eat and interact fairly normally within the group, they were sent to the Israel Primate Sanctuary (www.ipsf.org.il).

**Reporting Summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

The data used in this study are available from the corresponding author upon reasonable request.

**CODE AVAILABILITY**

The codes used in this study are available from the corresponding author upon reasonable request.

Received: 15 January 2021; Accepted: 9 July 2021; Published online: 02 August 2021

**REFERENCES**

1. Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. *N. Engl. J. Med.* **355**, 896–908 (2006).
2. Weaver, F. M. et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial. *JAMA* **7**, 63–73 (2009).
3. Williams, A. et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. *Lancet Neurol.* **9**, 581–91 (2010).
4. Okun, M. S. et al. Cognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARe trial. *Ann. Neurol.* **65**, 586–95 (2009).
5. Krauss, J. K., Yiann, J., Loher, T. J. & Aziz, T. Z. Deep brain stimulation for dystonia. *J. Clin. Neuropsychol.* **21**, 18–30 (2004).
6. Baizabal-Carvallo, J. F., Kagnoff, M. N., Jimenez-Shahed, J., Fekete, R. & Jankovic, J. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. *J. Neurol. Neurosurg. Psychiatry.** **85**, 567–72 (2014).
7. Goodman, W. K. & Alterman, R. L. Deep brain stimulation for intractable psychiatric disorders. *Ann. Rev. Med.* **63**, 511–24 (2012).
8. Lipsman, N. & Lozano, A. (eds) Deep Brain Stimulation for Neurological Disorders: Theoretical Background and Clinical Application (Springer, 2015).
9. Moran, A., Bergman, H., Israel, Z. & Bar-Gad, I. Subthalamic nucleus functional organization revealed by parkinsonian neuronal oscillations and synchrony. *Brain.** **131**, 3339–409 (2008).
10. Valisky, D. et al. Stop! border ahead: Automatic detection of subthalamic exit during deep brain stimulation surgery. *Mov. Disord.** **32**, 70–79 (2017).
11. Dass, S. et al. Capturing initial understanding and impressions of surgical therapy for Parkinson’s disease. *Front. Neurol.** **12**, 1–10 (2021).
12. Nicholson, G., Pereira, A. C. & Hall, G. M. Parkinson’s disease and anasthesia. *Bj. Br. Aneseth.** **89**, 904–916 (2002).
13. Raz, A., Elmier, D., Zaidel, A., Bergman, H. & Israel, Z. Propofol decreases neuronal population spiking activity in the subthalamic nucleus of parkinsonian patients. *Anesthes. Analg.** **111**, 1285–1289 (2010).
14. Hutchison, W. D., Lang, A. E., Dostrovsky, J. O. & Lozano, A. M. Pallidal neuronal activity: Implications for models of dystonia. *Ann. Neurol.* **53**, 480–8 (2003).
15. Purdon, P. L., Sampson, A., Pavone, K. J. & Brown, E. N. Clinical electro-encephalography for anesthesiologists: part I: background and basic signatures. *Anesthesiology** **123**, 937–960 (2015).
16. Baxt, A. et al. Neural effects of propofol-induced unconsciousness and its reversal using thalamic stimulation. *Elife.* 10, 1–28 (2021).
17. Långsjö, J. W. et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. *Anesthesiology** **100**, 1065–1071 (2004).
18. Långsjö, J. W. et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. *Anesthesiology** **99**, 614–623 (2003).

J. Guang et al.
48. Sobreira-Neto, M. A. et al. High frequency of sleep disorders in Parkinson’s disease and its relationship with quality of life. *Eur. Neurol.* **78**, 330–337 (2017).

49. Mizrahi-Kliger, A. D., Kaplan, A., Israel, Z., Delfains, M. & Bergman, H. Basal ganglia beta oscillations during sleep underlie Parkinsonian insomnia. *Proc. Natl. Acad. Sci. USA.* **117**, 17359–68 (2020).

50. Darraqa, M. et al. Evoked alpha power is reduced in disconnected consciousness during sleep and anesthesia. *Sci. Rep.* **8**, 16664 (2018).

51. Kurdi, M., Theerth, K. & Deva, R. Ketamine: current applications in anesthesia, pain, and critical care. *Anesth. Essays Res.* **8**, 283–90 (2014).

52. Green, S. M. & Johnson, N. E. Ketamine sedation for pediatric procedures: part 2, review and implications. *Ann Emerg Med.* **19**, 1033–46 (1990).

53. Sklar, G. S., Zukin, S. R. & Reilly, T. A. Adverse reactions to ketamine. *Anaesthesia.* **49**, 5–10 (1994).

54. Friedberg, B. L. Hypnotic doses of propofol block ketamine-induced hallucinations. *Plast. Reconstr. Surg.* **91**, 196–7 (1993).

55. Grace, R. F. The effect of variable-dose diazepam on dreaming and emergence abolition by a psychological technique. *Anaesthesia.* **36**, 183–7 (1981).

56. Recommendations for the design and analysis of in vivo electrophysiology studies. *J. Neurosci.* **38**, 5837–5839 (2018).

57. Rincón-Cortés, M. & Grace, A. A. Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress. *Behav. Brain Res.* **379**, 112367 (2020).

58. Moghaddam, B. Ketamine. (The MIT Press, 2021).

59. Goldberg, J. A., Rokni, U., Boraud, T., Vaadia, E. & Bergman, H. Spike synchronization in the cortex-basal ganglia networks of parkinsonian primates reflects global dynamics of the local field potentials. *J. Neurosci.* **24**, 6003–10 (2004).

60. Rivlin-Etzion, M. et al. Low-pass filter properties of basal ganglia-cortical-muscle loops in the normal and MPTP primate model of parkinsonism. *J. Neurosci.* **28**, 633–49 (2008).

61. Rosin, B. et al. Closed-loop deep brain stimulation is superior in ameliorating motor network disorders using neuromodulation. *Anesth. Essays Res.* **8**, 283–90 (2014).

62. Contreras, C. M., Mexicano, G. & Guzman-Flores, C. A stereotaxic brain atlas of the monkey: a pilot study. *Eur. J. Pharmacol.* **247**, 299–307 (1995).

63. Benazzouz, A. et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. *Eur. J. Pharmacol.* **427**, 24–8 (1997).

64. Heimer, G., Bar-Gad, I., Goldberg, J. A. & Bergman, H. Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinsonism. *J. Neurosci.* **22**, 7850–5 (2002).

65. Joshua, M., Elias, S., Levine, O. & Bergman, H. Quantifying the isolation quality of extracellularly recorded action potentials. *J. Neurosci. Methods* **178**, 350–356 (2009).

66. Mittelmann, R., Joshua, M., Adler, A. & Bergman, H. A noninvasive, fast and inexpensive tool for the detection of eye open/closed state in primates. *J. Neurosci. Methods* **178**, 350–356 (2009).

67. Mizrahi-Kliger, A. D., Kaplan, A., Israel, Z. & Bergman, H. Desynchronization of slow oscillations in the basal ganglia during natural sleep. *Proc. Natl. Acad. Sci. USA.* **115**, E4274–E4283 (2018).

68. Moran, A. & Bar-Gad, I. Revealing neuronal functional organization through the relation between multi-scale oscillatory extracellular signals. *J. Neurosci. Methods* **186**, 116–29 (2010).

**ACKNOWLEDGEMENTS**

We thank Tamar Ravins-Yaish for assistance with animal care; Atira Bick and ELSC neuroimaging unit (ENU) for assistance with the MRI scan; and Sharon Freeman for general assistance. We thank Anatoly Shaposhnikov for help in preparing the experimental setup. This work was supported by grants from the Israel Science Foundation, German Collaborative Research Center TRR295 (Returning dynamic motor network disorders using neuromodulation) Adelis and the Rosetrees Trust (to HBe) and research grant of the department of anesthesiology, Hadassah Medical Center (to SF).

**AUTHOR CONTRIBUTIONS**

J.G., H.Ba., O.B.Y., and S.F. contributed equally. O.B.Y., S.F., and H.Be. conceived of the research questions and built an experimental setup. J.G., H.Ba., O.B.Y., S.F., and U.W.R. collected the data. J.G., H.Ba., and O.B.Y. performed the data analysis. H.Ba., J.G., and H.Be. wrote the manuscript and J.G. made the figures. V.K. and Z.I. performed the necessary surgeries. H.Be. oversaw all aspects of the work. All authors have read, discussed, and approved the final version of the manuscript.

**COMPETING INTERESTS**

The authors declare no competing interest.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41531-021-00211-9.

Correspondence and requests for materials should be addressed to J.G.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021